Skip to content

Pre-discharge Influenza Vaccination in Patients Hospitalized for Acute Cardiac Conditions

Pre-discharge Influenza Vaccination in Patients Hospitalized for Acute Cardiac Conditions

Status
Recruiting
Phases
Phase 4
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT07617376
Enrollment
400
Registered
2026-06-01
Start date
2025-11-12
Completion date
2027-07-01
Last updated
2026-06-01

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Acute Heart Failure (AHF), Arrhythmias, Decompensated Chronic Heart Failure, Hypertension Emergency, Myocardial Infarction, Pulmonary Embolism Acute

Keywords

influenza vaccination, acute cardiac emergencies, pre-discharg vaccination

Brief summary

Patients hospitalized for acute cardiac conditions-including acute myocardial infarction, acute heart failure, pulmonary embolism, arrhythmias, and hypertensive emergencies-represent a heterogeneous population at very high risk of recurrent cardiovascular events. Influenza infection may act as a trigger for adverse cardiovascular events. Given the persistently low influenza vaccination uptake despite evidence-based benefits observed in vulnerable populations, including patients with cardiac conditions, new strategies to improve vaccination coverage are being explored. Recently, increasing attention has been directed toward an approach already used in fields such as neonatology, where vaccinations are administered prior to hospital discharge. In this investigator-initiated, single-center, randomized, open-label interventional study, we will evaluate whether influenza vaccination administered within 24 hours before hospital discharge in patients hospitalized for acute cardiac conditions is safe and effective in reducing subsequent infections, cardiovascular events, and mortality during the 6 months following hospitalization.

Interventions

BIOLOGICALInfluenza vaccination

Influenza vaccination pre-discharge in patients hospitalized for acute cardiac conditions

Sponsors

Wroclaw Medical University
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
PREVENTION
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Acute cardiac hospitalization, * Planned discharge home within the next 48 hours following completion of in-hospital treatment, * No prior influenza vaccination for the current influenza season.

Exclusion criteria

* History of a severe adverse reaction to influenza vaccination, * Allergy to any component of the vaccine to be administered, * Discharge to another hospital for continuation of treatment or discharge to a long-term care facility, * Antibiotic therapy to be continued after discharge.

Design outcomes

Primary

MeasureTime frameDescription
infection, unplanned cardiovascular hospitalization or cardiovascular death6 monthsFor the purposes of the study, infection was defined as an acute illness characterized by at least one of the following symptoms or events: * typical symptoms (malaise, fatigue, etc.), * self-measured body temperature of 38°C or higher, * the need for antipyretic / analgesic medication, * medical consultation (e.g. with general practitioner) due to infection, * unplanned hospitalization due to infection.

Countries

Poland

Contacts

CONTACTPiotr Kübler Kübler, Professor
piotr.kubler@umw.edu.pl48717364240
CONTACTMichal Tkaczyszyn, M.D., PhD
michal.tkaczyszyn@umw.edu.pl48 71 733 11 12
STUDY_CHAIRJan Biegus, Professor

Wroclaw Medical University

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Jun 2, 2026